ASLAN Pharmaceuticals today announced today announced that it plans to develop ASLAN003, its next generation inhibitor of dihydroorotate dehydrogenase (DHODH), in autoimmune conditions, such as multiple sclerosis (MS).
ASLAN003 is a highly selective and potent inhibitor of human DHODH (IC50 = 35 nM) and has been shown to be more than 30 times more potent at inhibiting the DHODH enzyme in cell free and cell-based assays than the first generation inhibitor teriflunomide. In preclinical studies, ASLAN003 was shown to be efficacious in animal models of MS and other autoimmune diseases. Based on the specificity, potency and favourable safety profile identified in earlier clinical studies, ASLAN believes ASLAN003 is a promising candidate for development in these diseases, where a pressing need for differentiated and convenient treatment options exists.
For more information, please refer to the English press release.